Benzinga
Benzinga
Benzinga
mardi, septembre 29

Wave Life Sciences Inc

WVENASDAQ
Trade with Public
Trade with Public
$3.64
-0.03-0.82%
À la clôture: Sep 29, 5:00 PM EST
$3.64
N/A
Après les heures: 4:36 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Wave Life Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Wave Life Sciences (WVE).

Price Target Range — 12 Quarters

Analyst Consensus — 18 Analysts

17Buy
1Hold
Consensus RatingBuy# Analysts18Avg. Consensus PT$23Upside to Avg. PT+536.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Sep 23, 2026JP MorganTessa RomeroDowngradeOverweight→Neutral—
Aug 4, 2026MizuhoSalim SyedPT CutOutperform$27→$23
More with Benzinga EdgeGet Access

Analyst Ratings News

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Analysts downgraded Ryder, Warner Bros. Discovery, Arbor Realty, Pershing Square and PepsiCo; Ryder and PepsiCo targets were cut.
Avi Kapoor

This PepsiCo Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

Analysts downgraded PepsiCo, RLJ Lodging Trust, Braskem.
Avi Kapoor

This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Wall Street analysts downgraded Rollins, Yum Brands, Alkami Technology, VICI Properties and Safehold, cutting targets for Rollins and Alkami.
Avi Kapoor

This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.
Avi Kapoor

PRO
JP Morgan Downgrades Wave Life Sciences to Neutral

JP Morgan analyst Tessa Romero downgrades Wave Life Sciences (NASDAQ:WVE) from Overweight to Neutral.
Benzinga Newsdesk

PRO
Mizuho Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $23

Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $27 to $23.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved